Literature DB >> 1812372

Porphyrins as contrast media.

J A Nelson1, U Schmiedl.   

Abstract

The interest in tissue distribution of variously labeled or otherwise detectable natural and synthetic porphyrins and porphyrin derivatives dates back well over 60 years. Although a considerable interest in fluorescent tumor localization and therapy dominates the history of porphyrin biodistribution studies, many investigators have evaluated the diagnostic and therapeutic characteristics of porphyrins with radioactive, radiopaque, and paramagnetic qualities. In this paper, a review of the use of porphyrins as nuclear medicine, X-ray, and NMR contrast agents is presented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812372     DOI: 10.1002/mrm.1910220243

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  4 in total

Review 1.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

2.  Manganese(III) porphyrins complexed with P22 virus-like particles as T1-enhanced contrast agents for magnetic resonance imaging.

Authors:  Shefah Qazi; Masaki Uchida; Robert Usselman; Riley Shearer; Ethan Edwards; Trevor Douglas
Journal:  J Biol Inorg Chem       Date:  2013-12-21       Impact factor: 3.358

3.  Small angle X-ray scattering study of meso-tetrakis (4-sulfonatophenyl) porphyrin in aqueous solution: a self-aggregation model.

Authors:  S C M Gandini; E L Gelamo; R Itri; M Tabak
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

4.  Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by MRI.

Authors:  G Marchal; Y Ni; P Herijgers; W Flameng; C Petré; H Bosmans; J Yu; W Ebert; C S Hilger; D Pfefferer; W Semmler; A L Baert
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.